What BIO-TECHNE Corp's SEC filings said

10-Q/A for 2026Q3, filed 12 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Pending Merger with Merck71 · importance in its document · 10-Q/A · 2026Q3
In June 2026, Bio-Techne entered into a merger agreement with Merck KGaA, Darmstadt, Germany, under which Merck’s wholly owned subsidiary will merge into Bio-Techne, which will survive as a wholly owned subsidiary. Bio-Techne shareholders…
Balance Sheet and Liquidity69 · importance in its document · 10-Q/A · 2026Q3
Cash and cash equivalents were $350.0 million at September 30, 2026, up from $264.7 million at June 30, 2026. The Company had $800.0 million available under its revolving line of credit, which matures August 31, 2027, and did not draw on…
Operating Margin Drivers59 · importance in its document · 10-Q/A · 2026Q3
Gross margin increased 4.5% to $196.6 million, but gross margin as a share of revenue edged down to 65.6% from 65.7%. Operating income declined 23.2% to $36.6 million from $47.7 million, reducing operating margin to 12.2% from 16.6%.…
Capital Expenditure Program59 · importance in its document · 10-Q/A · 2026Q3
Capital expenditures for fixed assets were $5.9 million in the first quarter of fiscal 2027, compared with $5.4 million in the first quarter of fiscal 2026. The Company expected approximately $28 million of additional capital expenditures…
Quarterly Dividend Declaration13 · importance in its document · 8-K exhibit · 4 Nov 2026
Bio-Techne’s Board declared a quarterly dividend of $0.08 per share for the quarter ended September 30, 2026. The dividend is payable November 23, 2026, to shareholders of record at the close of business on November 13, 2026. Payment is…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q/A · 2026Q3 filed 12 Nov 2026

Full report · Filing on EDGAR

Pending Merger with MerckImportance 71 · +1 more on this subject
In June 2026, Bio-Techne entered into a merger agreement with Merck KGaA, Darmstadt, Germany, under which Merck’s wholly owned subsidiary will merge into Bio-Techne, which will survive as a wholly owned subsidiary.…
Balance Sheet and LiquidityImportance 69
Cash and cash equivalents were $350.0 million at September 30, 2026, up from $264.7 million at June 30, 2026. The Company had $800.0 million available under its revolving line of credit, which matures August 31, 2027,…
Operating Margin DriversImportance 59
Gross margin increased 4.5% to $196.6 million, but gross margin as a share of revenue edged down to 65.6% from 65.7%. Operating income declined 23.2% to $36.6 million from $47.7 million, reducing operating margin to…
Capital Expenditure ProgramImportance 59
Capital expenditures for fixed assets were $5.9 million in the first quarter of fiscal 2027, compared with $5.4 million in the first quarter of fiscal 2026. The Company expected approximately $28 million of additional…
Geographic Revenue PerformanceImportance 56 · +1 more on this subject
United States revenue decreased 1.7% year over year to $152.7 million. EMEA excluding the United Kingdom grew 13.5% to $73.9 million, while United Kingdom revenue rose 4.0% to $13.7 million. APAC excluding Greater…
Operating Expense TrendsImportance 54
Selling, general and administrative expense increased 15.0% year over year to $133.7 million from $116.2 million. Research and development expense increased 8.7% to $26.3 million from $24.2 million, while total…
Market Demand TrendsImportance 49
Bio-Techne develops and sells biotechnology reagents, instruments, and services for research and clinical diagnostic markets worldwide. In the quarter ended September 30, 2026, consolidated organic revenue increased 7%…
Restructuring ChargesImportance 33
Fiscal 2026 restructuring actions focused on streamlining brand architecture and realigning brand-support functions, including operations and personnel; the Company expects related costs through fiscal 2027. Costs…
Income Tax Rate ChangesImportance 18
The effective income tax rate was 18.4% for the quarter ended September 30, 2026, compared with 20.4% in the prior-year quarter, reflecting the mix of net income and timing of discrete items. The forecasted tax rate…
DividendsImportance 18
Bio-Techne paid $12.6 million in cash dividends to common shareholders during the first quarter of fiscal 2027. The comparable payment in the first quarter of fiscal 2026 was $12.4 million. Management included cash…

8-K filings last 12 months

Press release attached to an 8-K4 Nov 2026 · 8-K
Read from the attached exhibit: Acquisition / Partnership / Divestiture · Quarterly Dividend Declaration
Press release attached to an 8-K23 Sept 2026 · 8-K
Read from the attached exhibit: Acquisition / Partnership / Divestiture
Results (release not read)12 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
Management change (filing not read)26 Jun 2026 · 8-K Item 5.02 · Routine · rule score 20
Results (release not read)6 May 2026 · 8-K Item 2.02 · Routine · rule score 20
Management change (filing not read)11 Feb 2026 · 8-K Item 5.02 · Routine · rule score 20
Results (release not read)4 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.